参考文献/References:
[1] Dietrich P,Hellerbrand C. Non-alcoholic fatty liver disease,obesity and the metabolic syndrome[J].Best Pract Res Clin Gastroenterol,2014,28(4):637-653.DOI:10.1016/j.bpg.2014.07.008.
[2] Kawano Y,Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease[J].J Gastroenterol,2013,48(4):434-441.DOI:10.1007/s00535-013-0758-5.
[3] Begriche K, Igoudjil A, Pessayre D, et al. Mitochondrial dysfunction in NASH:causes, consequences and possible means to prevent it[J].Mitochondrion, 2006,6(1):DOI:1-28.10.1016/j.mito.2005.10.004.
[4] LiS,Tan HY,Wang N, et al. The role of oxidative stress and antioxidants in liver diseases[J].Int J Mol Sci, 2015,16(11): 26087-26124.DOI:10.3390/ijms161125942.
[5] Komatsu M, Kageyama S, Ichimura Y. P62/SQSTM1/A170:physiology and pathology[J].Pharmacol Res,2012,66(6):457-462.10.DOI:1016/j.phrs.2012.07.004.
[6] Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway[J].Annu Rev Pharmacol Toxicol,2007,47(1):89-116.DOI:10.1146/annurev.pharmtox.46.120604.141046.
[7] Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress[J].Mol Cell Biol, 2003,23(22):8137-8151.DOI:10.1128/mcb.23.22.8137-8151.2003.
[8] Wang X, Hai CX. ROS acts as a double-edged sword in the pathogenesis of type 2 diabetes mellitus:is Nrf2 a potential target for the treatment?[J].Mini Rev Med Chem, 2011, 11(12):1082-1092.DOI:10.2174/138955711797247761.
[9] Lau A, Wang XJ, Zhao F, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency:direct interaction between Keap1 and P62[J].Mol Cell Biol,2010,30(13):3275-3285.DOI:10.1128/MCB.00248-10.
[10] Taguchi K, Fujikawa N, Komatsu M, et al. Keap1 degradation by autophagy for the maintenance of redox homeostasis[J].Proc Natl Acad Sci,2012,109(34):13561-13566.DOI:10.1073/pnas.1121572109.
[11] Jain A, Lamark T, Sjottem E, et al. P62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription[J].J Biol Chem, 2010,285(29):22576-22591.DOI:10.1074/jbc.M110.118976.
[12] Wang C, Cui Y, Li C, et al. Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet[J].Lipids Health Dis,2013,12(1):165.DOI:10.1186/1476-511X-12-165.
[13] Meakin PJ, Chowdhry S, Sharma RS, et al. Susceptibility of Nrf2-Null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance[J].Mol Cell Biol,2014,34(17): 3305-3320.DOI:10.1128/MCB.00677-14.
[14] Lee LY, Kohler UA, Zhang L, et al. Activation of the Nrf2-ARE pathway in hepatocytes protects against steatosis in nutritionally induced non-alcoholic steatohepatitis in mice[J].Toxicol Sci,2014,142(2):361-374.DOI:10.1093/toxsci/kfu184.
[15] Chowdhry S, Nazmy MH, Meakin PJ, et al. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis[J].Free Radic Biol Med,2010,48(2):357-371.DOI:10.1016/j.freeradbiomed.2009.11.007.
[16] Pierluigi R, Hannah D, Stephanie E, et al. Genetic Nrf2 overactivation inhibits the deleterious effects induced by hepatocyte-specific c-met deletion during the progression of NASH[J].Oxid Med Cell Longev,2017,2017:1-15.DOI:10.1155/2017/3420286.
[17] Komatsu M,Kurokawa H,Waguri S,et al.The selective autophagy substrate P62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1[J].Nat Cell Biol, 2010,12:399-403.DOI:10.1038/ncb2021
[18] Akiyama K, Warabi E, Okada K, et al. Deletion of both P62 and Nrf2 spontaneously results in the development of nonalcoholic steatohepatitis[J]. Exp Anim, 2018,67(2):201-218.DOI:10.1538/expanim.17-0112.
[19] Park JS, Dong HK, Da HL, et al. Concerted action of P62 and Nrf2 protects cells from palmitic acid-induced lipotoxicity[J].Biochem Biophys Res Commun,2015,466(1):131-137.DOI:10.1016/j.bbrc.2015.08.120.
[20] Lee DH, Park JS, Lee YS, et al. SQSTM1/P62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity[J].Autophagy, 2020,10: 1-25.DOI:10.1080/15548627.2020.1712108.
[21] Tao H, Zhang Y, Zeng X, et al. Niclosamide ethanolamine improves blood glycemic control and reduces hepatic steatosis in mice[J].Nat Med,2014, 20(11):1263-1269.DOI: 10.1038/nm.3699.
[22] Park JS,Lee YS,Lee DH,et al. Repositioning of niclosamide ethanolamine(NEN), an anthelmintic drug, for the treatment of lipotoxicity[J].Free Radic Biol Med,2019,137:143-157.DOI:10.1016/j.freeradbiomed.2019.04.030.
[23] Park H,Shima T,Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease[J].J Gastroenterol,2011,46(1):101-107.DOI:10.1007/s00535-010-0291-8.
[24] Nozaki Y,Fujita K,Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease[J].J Hepatol,2009,51(3):548-556.DOI:10.1016/j.jhep.2009.05.017.
[25] Lee DH,Han DH,Nam KT, et al. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis[J].Free Radic Biol Med,2016,99:520-532.DOI:10.1016/j.freeradbiomed.2016.09.009.